Charles J. Ryan, MD

Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, provides an update to the IMAAGEN trial, which explored the effects of abiraterone acetate (Zytiga) and low-dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nonmetastatic castration-resistant prostate cancer

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the effects he has seen abiraterone have in patients with metastatic castration-resistant prostate cancer (mCRPC).

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

Charles Ryan, MD, discusses community oncologist prescribing preferences for patients with prostate cancer or renal cell carcinoma.

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses the Unblinding of the COU-AA-302 Trial

Dr. Charles Ryan from the UCSF Helen Diller Family Comprehensive Cancer Center Discusses Neoadjuvant Abiraterone Acetate

Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.

Dr. Charles Ryan, from the UCSF Diller Family Comprehensive Cancer Center, on the COU-AA-302 Abiraterone Acetate Interim Analysis Results.